In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025, marks a dramatic escalation in the race to dominate the rapidly expanding weight-loss drug market and signals a strategic shift for Novo Nordisk under new leadership.
The Bidding War Intensifies
Novo Nordisk’s bold proposal offers $56.50 per share in cash upfront ($6 billion) plus an additional $21.25 per share in contingent value rights (CVRs) tied t...
